HC Wainwright Issues Positive Outlook for UNCY Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Free Report) – Equities research analysts at HC Wainwright lifted their Q4 2027 earnings per share (EPS) estimates for Unicycive Therapeutics in a note issued to investors on Tuesday, November 17th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $0.07 for the quarter, up from their previous forecast of $0.04. HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.16) per share.

A number of other brokerages also recently weighed in on UNCY. B. Riley Financial reaffirmed a “buy” rating and set a $20.00 price objective (down from $22.00) on shares of Unicycive Therapeutics in a research report on Wednesday, August 12th. Guggenheim reissued a “buy” rating and issued a $25.00 target price (down from $37.00) on shares of Unicycive Therapeutics in a report on Thursday, August 13th. Zacks Research upgraded Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 19th. Benchmark reaffirmed a “speculative buy” rating and set a $15.00 target price (up from $13.00) on shares of Unicycive Therapeutics in a report on Thursday, August 20th. Finally, Wall Street Zen lowered Unicycive Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.25.

View Our Latest Analysis on Unicycive Therapeutics

Unicycive Therapeutics Stock Performance

Shares of NASDAQ:UNCY opened at $3.70 on Wednesday. The company’s fifty day moving average is $4.14 and its two-hundred day moving average is $5.90. Unicycive Therapeutics has a 1-year low of $3.33 and a 1-year high of $8.74. The stock has a market capitalization of $103.05 million, a price-to-earnings ratio of -2.22 and a beta of 1.91.

Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.10.

Hedge Funds Weigh In On Unicycive Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Virtu Financial LLC grew its position in shares of Unicycive Therapeutics by 412.4% during the third quarter. Virtu Financial LLC now owns 59,484 shares of the company’s stock worth $279,000 after acquiring an additional 47,874 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Unicycive Therapeutics by 80.8% in the 3rd quarter. Goldman Sachs Group Inc. now owns 262,767 shares of the company’s stock worth $1,234,000 after acquiring an additional 117,463 shares during the period. Chicago Partners Investment Group LLC lifted its position in Unicycive Therapeutics by 26.0% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 26,966 shares of the company’s stock valued at $105,000 after purchasing an additional 5,556 shares during the last quarter. Pinnacle Wealth Planning Services Inc. bought a new stake in Unicycive Therapeutics in the 3rd quarter valued at about $36,000. Finally, Seven Fleet Capital Management LP lifted its position in Unicycive Therapeutics by 85.6% in the 2nd quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company’s stock valued at $521,000 after purchasing an additional 47,700 shares during the last quarter. Institutional investors and hedge funds own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

(Get Free Report)

Unicycive Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its lead program, oxylanthanum carbonate (OLC), is an oral phosphate binder being developed to help manage hyperphosphatemia, or elevated blood phosphate levels, in people with chronic kidney disease, including patients receiving dialysis. The company is also developing UNI-494, an investigational small-molecule therapy for acute kidney injury. These programs reflect Unicycive’s focus on conditions for which treatment options may be limited.

Further Reading

Earnings History and Estimates for Unicycive Therapeutics (NASDAQ:UNCY)

Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.